Aurisco Pharmaceutical Co Ltd Market Cap ($1.11 Billion)
Market Cap & Net Worth: Aurisco Pharmaceutical Co Ltd (605116)
Aurisco Pharmaceutical Co Ltd market cap. Aurisco Pharmaceutical Co Ltd (SHG:605116) has a market capitalization of $1.11 Billion (CN¥7.56 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #8168 globally and #1843 in its home market, demonstrating a 2.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aurisco Pharmaceutical Co Ltd's stock price CN¥18.60 by its total outstanding shares 406195234 (406.20 Million). Also see how efficiently does Aurisco Pharmaceutical Co Ltd generate cash for how efficiently the company converts equity into cash flow.
Aurisco Pharmaceutical Co Ltd Market Cap History (2020–2026)
Aurisco Pharmaceutical Co Ltd market cap history from 2020 to 2026. Data shows growth from $915.52 Million to $1.11 Billion (7.86% CAGR). Check current stock price of Aurisco Pharmaceutical Co Ltd for real-time trading data and today's change.
Aurisco Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aurisco Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Aurisco Pharmaceutical Co Ltd equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.85x
Aurisco Pharmaceutical Co Ltd's market cap is 0.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.54x
Aurisco Pharmaceutical Co Ltd's market cap is 3.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $915.52 Million | $721.44 Million | $157.23 Million | 1.27x | 5.82x |
| 2021 | $1.28 Billion | $803.36 Million | $168.71 Million | 1.59x | 7.59x |
| 2022 | $1.44 Billion | $1.01 Billion | $210.90 Million | 1.43x | 6.85x |
| 2023 | $1.52 Billion | $1.26 Billion | $289.42 Million | 1.20x | 5.25x |
| 2024 | $1.26 Billion | $1.48 Billion | $354.79 Million | 0.85x | 3.54x |
Competitor Companies of 605116 by Market Capitalization
Companies near Aurisco Pharmaceutical Co Ltd in the global market cap rankings as of November 9, 2026. Also see Aurisco Pharmaceutical Co Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Aurisco Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Aurisco Pharmaceutical Co Ltd (2020–2026)
Market capitalization of Aurisco Pharmaceutical Co Ltd from 2020 to today. Between 2020 and today, Aurisco Pharmaceutical Co Ltd's market cap moved from $915.52 Million to $ 1.11 Billion, with a yearly change of 7.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.11 Billion | -25.75% |
| 2025 | CN¥1.49 Billion | +18.61% |
| 2024 | CN¥1.26 Billion | -17.40% |
| 2023 | CN¥1.52 Billion | +5.21% |
| 2022 | CN¥1.44 Billion | +12.79% |
| 2021 | CN¥1.28 Billion | +39.89% |
| 2020 | CN¥915.52 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of Aurisco Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.11 Billion USD |
| MoneyControl | $1.11 Billion USD |
| MarketWatch | $1.11 Billion USD |
| marketcap.company | $1.11 Billion USD |
| Reuters | $1.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aurisco Pharmaceutical Co Ltd
Aurisco Pharmaceutical Co.,Ltd. engages in research, manufacturing, and marketing of pharmaceutical intermediates, specialty active pharmaceutical ingredients (API's), and formulations catering to the pharmaceutical market worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provid… Read more